Physician profile
John C Hahn
NPI 1538272091
$3,482.65
in general payments reported to CMS, 2019-2025
17 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $27.64 · 2021: $11.09 · 2022: $13.99 · 2023: $1,538 · 2024: $514 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,847 · Travel and Lodging: $1,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,847.04 |
| Travel and Lodging | $1,261.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $1,503.99 | 2023 | Phasix Mesh |
| Ardelyx, INC. | $262.33 | 2024-2025 | Ibsrela |
| Janssen Biotech, INC. | $247.51 | 2024-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $217.74 | 2025 | Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $205.89 | 2019-2025 | Entyvio, Eohilia |
| Abbvie INC. | $169.43 | 2020-2025 | |
| Ipsen Biopharmaceuticals, INC | $158.11 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $152.36 | 2024-2025 | Rezdiffra, Resmetirom |
| Allergan, INC. | $115.00 | 2019 | |
| Intercept Pharmaceuticals, INC. | $111.69 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $105.11 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.74 | 2024 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $54.90 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $34.51 | 2025 | Wegovy |
| Qol Medical, LLC | $21.26 | 2024 | Sucraid |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $13.99 | 2022 | |
| Boston Scientific Corporation | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.